FDA Abortion Pill Safety Review to Continue Into Next Year
The FDA will not publish its safety review of mifepristone until March, adding that it will impose no new restrictions on the drug before that point.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
4 publishers have covered this in 4 articles since 8 Oct 2026. The Hill published first, on 8 October at 02:33 UTC; CBS News Politics followed 7h 57m later. The most recent article, from STAT, appeared on 8 October at 15:02 UTC.
Outlets reporting it: The Hill (major outlet), CBS News Politics (major outlet), MedPageToday.com - medical news for physicians, STAT.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- The HillFDA: mifepristone review won't be done until March
- CBS News PoliticsFDA says its abortion pill safety review will continue into next year
- MedPageToday.com - medical news for physiciansFDA Says Its Safety Review of Abortion Pill Will Continue Into Next Year
- STATFDA says its safety review of abortion pill will continue into next year
Sources
Every article we clustered into this story. Headlines link to the publisher.
- FDA says its abortion pill safety review will continue into next year CBS News Politics ·
- FDA: mifepristone review won't be done until March The Hill ·
- FDA says its safety review of abortion pill will continue into next year STAT
- FDA Says Its Safety Review of Abortion Pill Will Continue Into Next Year MedPageToday.com - medical news for physicians
In this story
- FDA
- mifepristone